PATENT CLAIM ANALYSIS

Application Number: 15770074
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "303000"]

Abstract:
Disclosed in the present application is a compound of formula (I) as defined herein as well as a pharmaceutical composition comprising said compound. Further disclosed in the present application is the use of such pharmaceutical compositions for treating diseases, namely inter alia for use in the treatment of cancer, metabolic, inflammatory, autoimmune and viral diseases. The compounds disclosed herein are inhibitors of MNK1 and/or MNK2 kinases.

Claim (Index 9):
The compound according to  claim 1 , wherein Q is\n (i) a mono- or bicyclic aromatic carbocyclic ring system with 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring carbon atoms, wherein said ring system is unsubstituted or substituted with at least one substituent independently selected from (a) C 1-6 alkyl, C 2-6 alkenyl and C 2-6 alkynyl, wherein said C 1-6 alkyl, C 2-6 alkenyl and C 2-6 alkynyl is unsubstituted or independently substituted with at least one substituent independently selected from halogen, N(T 5 )(T 6 ), OT 7 , ST 7 , NO 2 , CN, C(O)OT 7 , C(O)N(T 5 )(T 6 ), OC(O)N(T 5 )(T 6 ), S(O) 2 T 7 , S(O) 2 OT 8  and S(O) 2 N(T 5 )(T 6 ), and (b) halogen, CF 3 , OT 1 , N(T 2 )(T 3 ), NHC(O)T 4 , NHC(O)T 9 , NHS(O) 2 T 4 , ST 1 , S(O) 2 T 4 , NO 2 , CN, C(O)H, C(O)OT 1 , C(O)N(T 2 )(T 3 ), C(O)T 4  and OC(O)N(T 2 )(T 3 ), and (c) a mono- or bicyclic aromatic heterocyclic ring system with 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms, wherein 1, 2, 3, 4 or 5 ring atom(s) is/are a hetero atom selected from N, O and S, and the remaining ring atoms are carbon atoms, and wherein said ring system is unsubstituted or substituted with at least one substituent independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halogen, CF 3 , OT 1 , N(T 2 )(T 3 ), NHC(O)T 4 , NHS(O) 2 T 4 , ST 1 , S(O) 2 T 4 , NO 2 , CN, C(O)H, C(O)OT 1 , C(O)N(T 2 )(T 3 ), C(O)T 4  and OC(O)N(T 2 )(T 3 ); and (d) a mono- or bicyclic aromatic carbocyclic ring system with 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring carbon atoms, wherein said ring system is unsubstituted or substituted with at least one substituent independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halogen, CF 3 , OT 1 , N(T 2 )(T 3 ), NHC(O)T 4 , NHS(O) 2 T 4 , ST 1 , S(O) 2 T 4 , NO 2 , CN, C(O)H, C(O)OT 1 , C(O)N(T 2 )(T 3 ), C(O)T 4  and OC(O)N(T 2 )(T 3 ); and (e) a monocyclic saturated or partially unsaturated non-aromatic carbocyclic ring system with 3, 4, 5, 6 or 7 carbon atoms, wherein said ring system is unsubstituted or substituted with at least one substituent independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halogen, CF 3 , OT 1 , N(T 2 )(T 3 ), NHC(O)T 4 , NHS(O) 2 T 4 , ST 1 , S(O) 2 T 4 , NO 2 , CN, C(O)H, C(O)OT 1 , C(O)N(T 2 )(T 3 ), C(O)T 4  and OC(O)N(T 2 )(T 3 ); and (f) a mono- or bicyclic saturated or partially unsaturated non-aromatic heterocyclic ring system with 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms, wherein 1, 2, 3, 4 or 5 ring atom(s) is/are a hetero atom selected from N, O and S, and the remaining ring atoms are carbon atoms, and wherein said ring system is unsubstituted or substituted with at least one substituent independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halogen, CF 3 , OT 1 , N(T 2 )(T 3 ), NHC(O)T 4 , NHS(O) 2 T 4 , ST 1 , S(O) 2 T 4 , NO 2 , CN, C(O)H, C(O)OT 1 , C(O)N(T 2 )(T 3 ), C(O)T 4  and OC(O)N(T 2 )(T 3 ); or (ii) a mono- or bicyclic aromatic heterocyclic ring system with 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms, wherein 1, 2, 3, 4 or 5 ring atom(s) is/are a hetero atom selected from N, O and S, and the remaining ring atoms are carbon atoms, and wherein said ring system is unsubstituted or substituted with at least one substituent independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halogen, CF 3 , OT 1 , N(T 2 )(T 3 ), NHC(O)T 4 , NHS(O) 2 T 4 , ST 1 , S(O) 2 T 4 , NO 2 , CN, C(O)H, C(O)OT 1 , C(O)N(T 2 )(T 3 ), C(O)T 4  and OC(O)N(T 2 )(T 3 ); or (iii) a monocyclic saturated or partially unsaturated non-aromatic carbocyclic ring system with 3, 4, 5, 6 or 7 carbon atoms, wherein said ring system is unsubstituted or substituted with at least one substituent independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halogen, CF 3 , OT 1 , N(T 2 )(T 3 ), NHC(O)T 4 , NHS(O) 2 T 4 , ST 1 , S(O) 2 T 4 , NO 2 , CN, C(O)H, C(O)OT 1 , C(O)N(T 2 )(T 3 ), C(O)T 4  and OC(O)N(T 2 )(T 3 ); or (iv) a mono- or bicyclic saturated or partially unsaturated non-aromatic heterocyclic ring system with 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13 or 14 ring atoms, wherein 1, 2, 3, 4 or 5 ring atom(s) is/are a hetero atom selected from N, O and S, and the remaining ring atoms are carbon atoms, and wherein said ring system is unsubstituted or substituted with at least one substituent independently selected from C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, halogen, CF 3 , OT 1 , N(T 2 )(T 3 ), NHC(O)T 4 , NHS(O) 2 T 4 , ST 1 , S(O) 2 T 4 , NO 2 , CN, C(O)H, C(O)OT 1 , C(O)N(T 2 )(T 3 ), C(O)T 4  and OC(O)N(T 2 )(T 3 ).

Metadata:
- Claim Count in Document: 2.0
- Percentile: 91.0
- Lexical Diversity: 1.53061
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14386313', '12991225', '13681230', '15677614', '13891961']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.812868273989206
- 35 USC 102 Novelty (BERT): 0.5334364437135786
- Combined Prediction Score: 0.7849250909616433
- Mean Citation Score: 340.981962
- Max Citation Score: 364.35355
- Similarity Product: 265.3537299867809

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test